MedTrace Logo

A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects

NCT03650608 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-04-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and PK parameters in healthy subjects.

Conditions

  • Healthy Subject

Interventions

DRUG

Cohort 1: HL217 Ophathalmic Solution QD

Cohort 1 (Once a day)

DRUG

Cohort 2: HL217 Ophathalmic Solution BID

Cohort 2 (Twice a day)

DRUG

Cohort 3: HL217 Ophthalmic Solution QID

Cohort 3 (Four times a day)

DRUG

Placebo Ophthalmic solution

Placebo

Sponsors & Collaborators

  • Hanlim Pharm. Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • David Bell · BioKinetic Europe

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-08-31
Completion
2017-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03650608 on ClinicalTrials.gov